HOME > What's New > NEW tumor marker assay for hepatocellular carcinoma (HCC), "Lumipulse® G PIVKA-Ⅱ"is coming soon!

What's New

NEW tumor marker assay for hepatocellular carcinoma (HCC), "Lumipulse® G PIVKA-Ⅱ"is coming soon!

update:2014.07.10

New tumor marker for hepatocellular carcinoma (HCC) in PIVKA-II testing.

Lumipulse® G PIVKA-Ⅱ is an immunoreaction cartridge for in vitro diagnostic (IVD) use with the LUMIPULSE® G System, which based on CLEIA technology for the quantitative measurement of PIVKA-II in human serum to be used in the auxiliary diagnosis of HCC.

Clinical background

Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), a PIVKA body of factor II of a blood-clotting factor (PIVKA-II also called DCP, Des-gamma carboxyprothrombin), specifically increase in patients with HCC. PIVKA-II has no correlation with AFP but they can be complementary markers. The sensitivity for HCC is highly increased when PIVKA-II is combined with AFP, thus PIVKA-II has been widely used as complementary markers of HCC in Japan.

PIVKA-II is assayed as a marker for diagnosis and response evaluation of HCC and is useful as an adjunct to the diagnosis of the recurrence. Hence PIVKA-II in conjunction with diagnostic imaging method is used for auxiliary diagnosis of HCC.

NEW tumor marker assay for hepatocellular carcinoma (HCC), "Lumipulse® G PIVKA-Ⅱ"is coming soon! NEW tumor marker assay for hepatocellular carcinoma (HCC), "Lumipulse® G PIVKA-Ⅱ"is coming soon!